24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
2012
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
15
Citations
NaN
KQI